Mizuho Securities Reiterates Buy Rating, $12 PT on IN8bio (INAB), Sees Latest Presentations as "Supportive of INAB's Drug-resistant Immunotherapy Platform"

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $12.00 price target on IN8bio Inc. (NASDAQ: INAB), following the company's AACR presentations.

The analyst comments: "INAB’s AACR presentations provided updates on the company’s gamma delta T cell pipeline with 1) initial translational data from the Phase I study of INB-200 (MGMT-modified DRI gamma-delta T cells) in combination with temozolomide (TMZ) in glioblastoma multiforme (GBM) and 2) preclinical data of INB-300, a next-generation candidate that is engineered with a chlorotoxin (CLTX) -directed CAR construct. We see the updates as supportive of INAB’s drug-resistant immunotherapy (DRI) platform and the ongoing and planned clinical initiation in GBM."

For an analyst ratings summary and ratings history on IN8bio Inc. click here. For more ratings news on IN8bio Inc. click here.

Shares of IN8bio Inc. closed at $4.12 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)